In total, less than 20% of the genes involved in HSPG biosynthesis were differentially expressed in metastatic tumors versus nearly 40% in non-metastatic tumors [59], allowing for the potential of these genes to serve as biomarkers for staging of colorectal cancer. This evidence concerns the gene HSPG2 and metastatic neoplasm.